BHVN250117C50000
- 0.36
- +0.11+44.00%
Biohaven Newsroom
Bernstein Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $63
H.C. Wainwright Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $56 to $69
Biohaven Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $61
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Biohaven Analyst Ratings
BTIG Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $59
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $69
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Biohaven Ltd.: Buy Rating Affirmed Amid Promising Drug Prospects and Strategic FDA Engagement
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Vigil Neuroscience Inc (VIGL) and Biohaven Ltd. (BHVN)
Promising Potential of Biohaven's Taldefgrobep Alfa in Obesity Treatment and Niche SMA Market Justifies Buy Rating
Biohaven Is Maintained at Outperform by RBC Capital
Biohaven Analyst Ratings
RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating